VRTXVertex Pharmaceuticals

$523.97+28% 1Y

What is the market doing?

Mixed

No clear lean: nothing decisive, though in an uptrend.

1 good, 1 neutral, 1 without data
TrendUptrendderived · Oct 23, 2026

In an uptrend, above its rising 50- and 200-day averages. Price is +10% vs its 200-day average.

Short interest1.8% of sharesFINRA · Sep 30, 2026

Lightly shorted, settled Sep 30, 2026, about a week of normal trading to cover. Down 4.5% since the previous count, down from 1.9% of shares outstanding three months ago.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

1-year returnbetter than 67% of the market
vs 200-day avgbetter than 72% of the market

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How VRTX is trading

Vertex Pharmaceuticals is +28% over the past year while the S&P 500 is +16%: 12 points ahead of the market.

+28%

1-year return · S&P 500 +16%

vs 200-day average
+9.9%

vs 200-day average · close to trend

RSI (14)
59

RSI (14) · neutral

Below its 52-week high
6.1%

Below its 52-week high

Oct 15, 2024$366.54 – $558.12 · dashed line: 200-day averageOct 23, 2026
Details›
Last close2026-10-23
$523.97
1 monthS&P 500 −0.94%
+0.24%
1 yearS&P 500 +16%
+28%
5 yearsS&P 500 +86%
+192%
vs 50-day average$522.13
+0.35%
52-week high
$558.12
52-week low
$409.47
Annualised volatility
33%
Calendar-year price return
YearReturn
2026 (year to date)+16%
2025+13%
2024−1.0%
2023+41%
2022+32%
2021−7.1%
2020+7.9%
2019+32%
2018+11%
2017+103%
Average return by calendar month, 2016–2026
MonthYearsPositiveAverage
Jan109 of 10+9.1%
Feb103 of 10−1.3%
Mar106 of 10+3.6%
Apr106 of 10+0.87%
May105 of 10+1.4%
Jun109 of 10+5.1%
Jul116 of 11+2.3%
Aug117 of 11+1.3%
Sep113 of 11−3.1%
Oct117 of 11−1.1%
Nov107 of 10+3.6%
Dec105 of 10+0.23%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.

Where the price stands

Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.

What it has returned

With dividends, year by year, month by month, and by calendar month on average.